Sagimet Biosciences Inc. SGMT
10.13 USD -0.09 (-0.88%)
Regular-session close
10.13 0.00 0.00%
After hours · Nov 16, 4:26 PM ET
9.91 Day range 10.46
4.50 52-week range 11.45
- YTD
- +71.11%
- 1 year
- +30.71%
News
defenseworld.net ACT Capital Partners L.P. Makes New $593,000 Investment in Sagimet Biosciences Inc. $SGMT ACT Capital Partners L.P. purchased a new position in shares of Sagimet Biosciences Inc. (NASDAQ: SGMT) in the third quarter, according to its most recent disclosure with the Securities and Exchange…
globenewswire.com Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates FOSTER CITY, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key…benzinga.com Sagimet Biosciences Doses First Patient In AURORA, Pivotal U.S. Phase 3 Clinical Trial Of Denifanstat In Adults With Moderate To Severe Acne With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner…
